Table 1.
Serum average levels and standard deviation (SD) of 16 markers: sEGFR, FGF-basic, follistatin, G-CSF, HGF, sHER2/neu, sIL-6Rα, leptin, osteopontin, PECAM-1, PDGF-AB/BB, prolactin, SCF, sTIE-2, sVEGFR-1 and sVEGFR-2 in tested groups.
| Angiogenesis Marker | Ovarian Cancer | Control Group | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type I | Type II | Total | Non-Malignant Tumor | Healthy Subjects | Total | |||||||
| Average | SD | Average | SD | Average | SD | Average | SD | Average | SD | Average | SD | |
| sEGFR | 20,342.13 | 5845.31 | 20,295.90 | 8421.43 | 20,309.43 | 20,309.43 | 21,309.90 | 6318.37 | 22,883.43 | 9007.22 | 22,009.25 | 7633.25 |
| FGF-basic | 180.48 | 44.22 | 203.77 | 63.91 | 196.95 | 196.95 | 179.00 | 52.12 | 180.85 | 52.60 | 179.82 | 52.10 |
| Follistatin | 685.78 | 317.57 | 1042.48 | 844.22 | 938.08 | 938.08 | 547.91 | 232.49 | 629.53 | 322.66 | 584.19 | 277.84 |
| G-CSF | 92.53 | 26.26 | 109.25 | 49.04 | 104.36 | 104.36 | 88.79 | 23.68 | 87.51 | 25.59 | 88.22 | 24.44 |
| sHER2/neu | 3320.85 | 948.04 | 4091.06 | 2061.63 | 3865.63 | 3865.63 | 3563.75 | 1273.51 | 4428.57 | 2414.32 | 3948.11 | 1908.16 |
| HGF | 1440.99 | 779.83 | 1936.05 | 1028.92 | 1791.16 | 1791.16 | 1305.13 | 544.67 | 1444.71 | 711.23 | 1367.17 | 625.01 |
| sIL-6Rα | 15,154.04 | 4441.99 | 17,100.30 | 9621.15 | 16,530.66 | 16,530.66 | 14,733.51 | 5632.62 | 17,920.81 | 12,282.34 | 16,150.09 | 9289.22 |
| Leptin | 7928.88 | 7133.65 | 5892.49 | 6349.54 | 6488.51 | 6488.51 | 11,162.45 | 9759.36 | 12,370.69 | 14,333.84 | 11,699.44 | 11,963.72 |
| Osteopontin | 46,882.40 | 19,429.79 | 73,250.94 | 34,155.80 | 65,533.32 | 65,533.32 | 34816.71 | 15,300.22 | 38,185.47 | 20,838.74 | 36,313.94 | 17,962.64 |
| PDGF-AB/BB | 4396.93 | 2274.18 | 5397.20 | 2941.45 | 5104.44 | 5104.44 | 3653.87 | 1517.89 | 4007.50 | 2120.66 | 3811.04 | 1810.25 |
| PECAM-1 | 4411.84 | 996.33 | 4748.20 | 1674.27 | 4649.75 | 4649.75 | 4461.57 | 1524.40 | 4981.73 | 2088.27 | 4692.75 | 1806.74 |
| Prolactin | 11,688.28 | 9112.09 | 8920.90 | 5128.69 | 9730.87 | 9730.87 | 13,006.48 | 14,247.64 | 8799.15 | 6513.54 | 11,136.55 | 11,618.07 |
| SCF | 183.67 | 56.25 | 201.16 | 84.71 | 196.04 | 196.04 | 191.02 | 64.48 | 208.57 | 108.36 | 198.82 | 86.76 |
| sTIE-2 | 7697.06 | 2707.86 | 8890.87 | 4578.14 | 8541.46 | 8541.46 | 7824.73 | 2841.97 | 7886.31 | 3240.18 | 7852.10 | 3011.00 |
| sVEGFR-1 | 323.51 | 200.50 | 373.64 | 237.94 | 358.96 | 358.96 | 288.61 | 122.69 | 292.56 | 150.46 | 290.37 | 135.08 |
| sVEGFR-2 | 2906.88 | 1024.60 | 3347.97 | 1631.41 | 3218.87 | 3218.87 | 3128.36 | 1127.17 | 3520.94 | 1827.38 | 3302.84 | 1485.19 |
| CA125 | 344.68 | 536.27 | 1053.88 | 1312.09 | 853.85 | 1184.66 | 44.75 | 82.41 | - | - | - | - |
| HE4 | 258.78 | 399.07 | 760.70 | 942.74 | 619.14 | 851.91 | 50.22 | 13.88 | - | - | - | - |
sEGFR: soluble epidermal growth factor receptor; FGF-basic: basic fibroblast growth factor; G-CSF: granulocyte colony-stimulating factor; sHER2/neu:soluble human epidermal growth factor receptor 2; HGF: hepatocyte growth factor; sIL-6Rα: soluble interleukin 6; PDGF-AB/BB: platelet-derived growth factor AB/BB; PECAM-1: platelet and endothelial cell adhesion molecule 1; SCF: stem cell factor; sTIE-2: soluble receptor tyrosine kinase; sVEGFR: soluble vascular endothelial growth factor receptor; CA125: cancer antigen 125; HE4: human epididymis protein 4; SD: standard deviation.